Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 716

1.

Peripheral nervous system disease in Systemic Lupus Erythematosus: Results from an international, inception cohort study.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, Svenungsson E, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Rheumatol. 2019 Aug 7. doi: 10.1002/art.41070. [Epub ahead of print]

PMID:
31390162
2.

Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies.

Wilkinson MGL, Radziszewska A, Wincup C, Ioannou Y, Isenberg DA, Manson JJ, Jury EC.

Rheumatology (Oxford). 2019 Jul 10. pii: kez252. doi: 10.1093/rheumatology/kez252. [Epub ahead of print]

PMID:
31292651
3.

Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?

Freitas S, Mozo Ruiz M, Costa Carneiro A, Isenberg DA.

Clin Exp Rheumatol. 2019 Jul 8. [Epub ahead of print]

PMID:
31287404
4.

Author Correction: New therapies for systemic lupus erythematosus - past imperfect, future tense.

Murphy G, Isenberg DA.

Nat Rev Rheumatol. 2019 Aug;15(8):509. doi: 10.1038/s41584-019-0262-2.

PMID:
31270422
5.

Review of major endocrine abnormalities in patients with systemic lupus erythematosus.

Muñoz C, Isenberg DA.

Clin Exp Rheumatol. 2019 Jun 6. [Epub ahead of print]

PMID:
31172923
6.

New therapies for systemic lupus erythematosus - past imperfect, future tense.

Murphy G, Isenberg DA.

Nat Rev Rheumatol. 2019 Jul;15(7):403-412. doi: 10.1038/s41584-019-0235-5. Review. Erratum in: Nat Rev Rheumatol. 2019 Aug;15(8):509.

PMID:
31165780
7.

Present and novel biologic drugs in primary Sjögren's syndrome.

Fasano S, Isenberg DA.

Clin Exp Rheumatol. 2019 Apr 26. [Epub ahead of print] Review.

PMID:
31025931
8.

Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin P, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG.

J Rheumatol. 2019 Apr 15. pii: jrheum.181338. doi: 10.3899/jrheum.181338. [Epub ahead of print]

PMID:
30988130
9.

Renal transplantation for lupus nephritis: non-adherence and graft survival.

Ntatsaki E, Vassiliou VS, Velo-Garcia A, Salama AD, Isenberg DA.

Lupus. 2019 Apr;28(5):651-657. doi: 10.1177/0961203319842641. Epub 2019 Apr 13.

PMID:
30982400
10.

Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin P, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Steinsson K, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG.

Arthritis Rheumatol. 2019 Aug;71(8):1297-1307. doi: 10.1002/art.40859. Epub 2019 May 29.

PMID:
30771242
11.

Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.

Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón G, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet E.

Rheumatology (Oxford). 2019 Jul 1;58(7):1259-1267. doi: 10.1093/rheumatology/kez014.

PMID:
30753683
12.

Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.

Wirestam L, Enocsson H, Skogh T, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace D, Isenberg DA, Rahman A, Merrill J, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C.

J Rheumatol. 2019 May;46(5):492-500. doi: 10.3899/jrheum.180713. Epub 2019 Jan 15.

13.

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort.

Mendel A, Bernatsky SB, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon JP, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin PR, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet É.

Ann Rheum Dis. 2019 Jul;78(7):1010-1012. doi: 10.1136/annrheumdis-2018-214434. Epub 2018 Dec 20. No abstract available.

14.

Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients.

Magill L, Adriani M, Berthou V, Chen K, Gleizes A, Hacein-Bey-Abina S, Hincelin-Mery A, Mariette X, Pallardy M, Spindeldreher S, Szely N, Isenberg DA, Manson JJ, Jury EC, Mauri C.

Front Immunol. 2018 Dec 5;9:2865. doi: 10.3389/fimmu.2018.02865. eCollection 2018.

15.

PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome.

McDonnell TCR, Willis R, Pericleous C, Ripoll VM, Giles IP, Isenberg DA, Brasier AR, Gonzalez EB, Papalardo E, Romay-Penabad Z, Jamaluddin M, Ioannou Y, Rahman A.

Front Immunol. 2018 Oct 22;9:2413. doi: 10.3389/fimmu.2018.02413. eCollection 2018.

16.

Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.

Quelhas da Costa R, Aguirre-Alastuey ME, Isenberg DA, Saracino AM.

JAMA Dermatol. 2018 Dec 1;154(12):1432-1440. doi: 10.1001/jamadermatol.2018.3793.

PMID:
30383114
17.

Under crossfire: thromboembolic risk in systemic lupus erythematosus.

Ramirez GA, Efthymiou M, Isenberg DA, Cohen H.

Rheumatology (Oxford). 2019 Jun 1;58(6):940-952. doi: 10.1093/rheumatology/key307.

PMID:
30380105
18.

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Rheumatol. 2019 Feb;71(2):281-289. doi: 10.1002/art.40764. Epub 2019 Jan 18.

19.

How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project).

Brito-Zerón P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T, Seror R, Li X, Baldini C, Gottenberg JE, Danda D, Quartuccio L, Priori R, Hernandez-Molina G, Armagan B, Kruize AA, Kwok SK, Kvarnström M, Praprotnik S, Sène D, Bartoloni E, Solans R, Rischmueller M, Suzuki Y, Isenberg DA, Valim V, Wiland P, Nordmark G, Fraile G, Bootsma H, Nakamura T, Giacomelli R, Devauchelle-Pensec V, Knopf A, Bombardieri M, Trevisani VF, Hammenfors D, Pasoto SG, Retamozo S, Gheita TA, Atzeni F, Morel J, Vollenveider C, Horvath IF, Sivils KL, Olsson P, De Vita S, Sánchez-Guerrero J, Kilic L, Wahren-Herlenius M, Mariette X, Ramos-Casals M; Sjögren Big Data Consortium.

Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):102-112. Epub 2018 Aug 14.

20.

Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Stoll T, Buyon J, Mahler M, Fritzler MJ.

Arthritis Care Res (Hoboken). 2019 Jul;71(7):893-902. doi: 10.1002/acr.23712. Epub 2019 Jun 12.

PMID:
30044551
21.

Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome.

Ripoll VM, Pregnolato F, Mazza S, Bodio C, Grossi C, McDonnell T, Pericleous C, Meroni PL, Isenberg DA, Rahman A, Giles IP.

J Autoimmun. 2018 Sep;93:114-123. doi: 10.1016/j.jaut.2018.07.002. Epub 2018 Jul 19.

22.

CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α.

Piper CJM, Wilkinson MGL, Deakin CT, Otto GW, Dowle S, Duurland CL, Adams S, Marasco E, Rosser EC, Radziszewska A, Carsetti R, Ioannou Y, Beales PL, Kelberman D, Isenberg DA, Mauri C, Nistala K, Wedderburn LR.

Front Immunol. 2018 Jun 22;9:1372. doi: 10.3389/fimmu.2018.01372. eCollection 2018.

23.

Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis.

Ntatsaki E, Velo-Garcia A, Vassiliou VS, Salama AD, Isenberg DA.

Clin Rheumatol. 2018 Sep;37(9):2399-2404. doi: 10.1007/s10067-018-4115-1. Epub 2018 May 11.

24.

Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus.

Carreira PL, Isenberg DA.

Rheumatology (Oxford). 2019 Mar 1;58(3):382-387. doi: 10.1093/rheumatology/key064.

PMID:
29660084
25.

Use of direct oral anticoagulants in antiphospholipid syndrome.

Cohen H, Efthymiou M, Isenberg DA.

J Thromb Haemost. 2018 Jun;16(6):1028-1039. doi: 10.1111/jth.14017. Epub 2018 May 13. Review.

PMID:
29624847
26.

Very delayed lupus nephritis: a report of three cases and literature review.

Alexandre AR, Carreira PL, Isenberg DA.

Lupus Sci Med. 2018 Jan 12;5(1):e000241. doi: 10.1136/lupus-2017-000241. eCollection 2018.

27.

Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.

Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Sam Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN.

Rheumatology (Oxford). 2018 Apr 1;57(4):677-687. doi: 10.1093/rheumatology/kex444.

28.

Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin P, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, Chatham W, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1478-1487. doi: 10.1002/acr.23509. Epub 2018 Sep 1.

PMID:
29316357
29.

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.

McCarthy EM, Sutton E, Nesbit S, White J, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register.

Rheumatology (Oxford). 2018 Mar 1;57(3):470-479. doi: 10.1093/rheumatology/kex395.

30.

Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach.

Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Fortin PR, Gladman DD, Sanchez-Guerrero J, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, Clarke AE.

Arthritis Care Res (Hoboken). 2018 Sep;70(9):1294-1302. doi: 10.1002/acr.23480. Epub 2018 Aug 17.

31.

A review of inflammatory idiopathic myopathy focusing on polymyositis.

Clark KEN, Isenberg DA.

Eur J Neurol. 2018 Jan;25(1):13-23. doi: 10.1111/ene.13357. Epub 2017 Aug 17. Review.

PMID:
28816394
32.

TRIM21 and the Function of Antibodies inside Cells.

Rhodes DA, Isenberg DA.

Trends Immunol. 2017 Dec;38(12):916-926. doi: 10.1016/j.it.2017.07.005. Epub 2017 Aug 11. Review.

PMID:
28807517
33.

Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque.

Smith E, Croca S, Waddington KE, Sofat R, Griffin M, Nicolaides A, Isenberg DA, Torra IP, Rahman A, Jury EC.

Sci Immunol. 2016 Dec 2;1(6). pii: eaah4081. doi: 10.1126/sciimmunol.aah4081.

PMID:
28783690
34.

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment.

Cohen H, Hunt BJ, Efthymiou M, Mackie IJ, Khamashta M, Isenberg DA; RAPS Trial Investigators.

Curr Rheumatol Rep. 2017 Aug;19(8):50. doi: 10.1007/s11926-017-0675-3. Review.

35.

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.

McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register.

Rheumatology (Oxford). 2017 Jun 1;56(6):1049. doi: 10.1093/rheumatology/kex218. No abstract available.

PMID:
28549192
36.

The immunological personality of close relatives of SLE patients.

Salaman MR, Isenberg DA.

Lupus. 2017 Dec;26(14):1513-1516. doi: 10.1177/0961203317707826. Epub 2017 May 23.

37.

Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity.

Taher TE, Bystrom J, Ong VH, Isenberg DA, Renaudineau Y, Abraham DJ, Mageed RA.

Clin Rev Allergy Immunol. 2017 Oct;53(2):237-264. doi: 10.1007/s12016-017-8609-4. Review.

38.

The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.

McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register.

Rheumatology (Oxford). 2017 Jun 1;56(6):1041-1043. doi: 10.1093/rheumatology/kex044. No abstract available. Erratum in: Rheumatology (Oxford). 2017 Jun 1;56(6):1049.

39.

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Buyon J, Mahler M, Fritzler MJ.

Lupus. 2017 Sep;26(10):1051-1059. doi: 10.1177/0961203317692437. Epub 2017 Feb 23.

PMID:
28420054
40.

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.

Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, Leandro MJ.

Rheumatology (Oxford). 2017 Jul 1;56(7):1227-1237. doi: 10.1093/rheumatology/kex067.

41.

Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness.

Guerreiro Castro S, Isenberg DA.

Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85. doi: 10.1177/1759720X17690474. Epub 2017 Mar 1. Review.

42.

Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy.

Bezzina OM, Gallagher P, Mitchell S, Bowman SJ, Griffiths B, Hindmarsh V, Hargreaves B, Price EJ, Pease CT, Emery P, Lanyon P, Bombardieri M, Sutcliffe N, Pitzalis C, Hunter J, Gupta M, McLaren J, Cooper AM, Regan M, Giles IP, Isenberg DA, Saravanan V, Coady D, Dasgupta B, McHugh NJ, Young-Min SA, Moots RJ, Gendi N, Akil M, MacKay K, Ng WF, Robinson LJ; UK Primary Sjögren's Syndrome Registry.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1714-1723. doi: 10.1002/acr.23165. Epub 2017 Oct 9.

43.

Review by Hui-Yuen et al. Targeted B-cell therapies in the treatment of adult and paediatric systemic lupus erythematosus.

Isenberg DA.

Lupus. 2017 Jul;26(8):900. doi: 10.1177/0961203316680894. Epub 2016 Nov 30. No abstract available.

PMID:
27909159
44.

Comment on: Musculoskeletal complication of haematological disease: Reply.

Isenberg DA, Morais SA.

Rheumatology (Oxford). 2017 Feb;56(2):321. doi: 10.1093/rheumatology/kew373. Epub 2016 Nov 11. No abstract available.

PMID:
27837049
45.

Autoimmune gastrointestinal complications in patients with systemic lupus erythematosus: case series and literature review.

Alves SC, Fasano S, Isenberg DA.

Lupus. 2016 Dec;25(14):1509-1519. Epub 2016 Jun 20. Review.

PMID:
27329649
46.

Differences in disease phenotype and severity in SLE across age groups.

Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA; UK JSLE Study Group.

Lupus. 2016 Dec;25(14):1542-1550. Epub 2016 May 4.

47.

The diagnosis and management of the haematologic manifestations of lupus.

Velo-García A, Castro SG, Isenberg DA.

J Autoimmun. 2016 Nov;74:139-160. doi: 10.1016/j.jaut.2016.07.001. Epub 2016 Jul 25. Review.

PMID:
27461045
48.

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.

Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA; RAPS trial investigators.

Lancet Haematol. 2016 Sep;3(9):e426-36. doi: 10.1016/S2352-3026(16)30079-5.

49.

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.

Arachchillage DR, Mackie IJ, Efthymiou M, Chitolie A, Hunt BJ, Isenberg DA, Khamashta M, Machin SJ, Cohen H.

J Thromb Haemost. 2016 Nov;14(11):2177-2186. doi: 10.1111/jth.13475. Epub 2016 Sep 30.

50.

CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes.

Garaud S, Taher TE, Debant M, Burgos M, Melayah S, Berthou C, Parikh K, Pers JO, Luque-Paz D, Chiocchia G, Peppelenbosch M, Isenberg DA, Youinou P, Mignen O, Renaudineau Y, Mageed RA.

Cell Mol Immunol. 2018 Feb;15(2):158-170. doi: 10.1038/cmi.2016.42. Epub 2016 Aug 8.

Supplemental Content

Loading ...
Support Center